Table 2.
The effects of tetrac derivatives
| Cell cycle [5, 59, 89] | Angiogenesis [5, 18, 38, 89] | Others [5, 19, 59, 89, 90] |
| CCND1 ↓ (Tetrac, NDAT) | Anti-angiogenic: | HIF1A ↓ (tetrac, NDAT) |
| THBS1 ↑ (tetrac, NDAT) | TP53 ↑ (NDAT) | |
| Cell proliferation [5, 19, 38, 59, 89] | RRM2B ↑ (NDAT) | |
| CBY1 ↑ (tetrac, NDAT) | Angiogenic: | p21 ↑ (NDAT) |
| CTNNA1 ↓ (NDAT) | VEGFA ↓ (tetrac, NDAT) | |
| CTNNA2 ↓ (NDAT) | bFGF ↓ (tetrac, NDAT) | |
| CTNNB1 ↓ (tetrac) | ||
| β-catenin ↓ (tetrac) | Metastasis [5, 89] | |
| PCNA ↓ (tetrac, NDAT) | MMP-2 ↓ (tetrac, NDAT) | |
| c-Myc ↓ (tetrac, NDAT) | MMP-9 ↓ (tetrac, NDAT) | |
| EGFR ↓ (NDAT) | MMP-13 ↓ (tetrac) | |
| Apoptosis [5, 38, 59, 66] | Immune checkpoint [45] | |
| Anti-apoptotic: | PD-L1 ↓ (NDAT) | |
| MCL1 ↓ (NDAT) | ||
| XIAP ↓ (tetrac, NDAT) | Chemo sensitization [5, 89] | |
| HMGA2 ↓ (tetrac) | ||
| Proapoptotic: | ST6Gal1 ↓ (NDAT) | |
| BCL2L14 ↑ (NDAT) | ||
| CASP2 ↑ (NDAT) | ||
| BAD ↑ (NDAT) |